📰 Dose Level News
Page 3 - Dose Level News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dose Level. Real-time updates on events, politics, business and more.
January 12, 2023
Precigen, Inc. presented pipeline and corporate updates at the 41st Annual J.P. Morgan Healthcare Conference. PRGN-2012 AdenoVerse™ Immunotherapy in RRP. Overview: PRGN-2012 is an investigational... | January 12, 2023
December 13, 2022
– Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow – – PRGN-3006...
November 9, 2022
– Company will host virtual R&D event in early January 2023, timed to coincide with the 41st Annual JP Morgan Healthcare Conference, to showcase complete...
August 9, 2022
Precigen, Inc. (NASDAQ:NASDAQ:PGEN) Q2 2022 Earnings Conference Call August 08, 2022 04:30 PM ET Company Participants Steven Harasym - Vice President and Head of Investor Relations Helen...
August 8, 2022
– Enrollment complete in Phase 1 study of PRGN-3006 UltraCAR-T® in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; Mayo...
June 24, 2022
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
June 13, 2022
- 82% ORR (9 of 11 patients) and 82% (9 of 11 patients) CR rate documented after anbal-cel treatment to the patients in relapsed/refractory larg...
June 11, 2022
-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose...
June 8, 2022
PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Months Among Evaluable CAR T Relapsed SubjectsPBCAR0191 Achieved Peak CAR T Cell Expansion Matching Data from Autologous CAR T Peak Expansion in Long Term Durable RespondersPBCAR19B CAR T Cell Manuf...
May 9, 2022
– Fast Track designation received for PRGN-3006 UltraCAR-T®, an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly...